 |
Cancer biology drives personalized management ... |
|
|
|
1 - 11 |
|
|
Appropriate surgery (RO) remains the milestone ...
|
|
|
|
12 - 13 |
|
|
We can do better - Decisions on Primary Prevention |
|
|
|
14 - 15 |
|
|
Prophylactic total gastrectomy for gastric cancer |
|
|
|
16 - 18 |
|
|
Preventing CDH1 Mutation Carriers |
|
|
|
19 - 21 |
|
|
Prevention of hereditary cancer syndromes |
|
|
|
22 - 24 |
|
|
Risk-reducing surgery in the prevention of hereditary cancer syndromes |
|
|
|
25 - 27 |
|
|
Genomewide Association Studies – Strengthens and Challenges in the Clinic ...
|
|
|
|
28 - 31 |
10.2122/gbc.2006.0059 |
|
The importance of surgical margin control in breast-conserving therapy...
|
|
|
|
32 - 33 |
10.2122/gbc.2006.0060 |
|
Reducing local recurrence after Breast-conserving surgery for breast cancer |
|
|
|
34 - 36 |
10.2122/gbc.2007.0061 |
|
Increased risk of local recurrence after breast-conserving therapy in young patients |
|
|
|
37 - 38 |
10.2122/gbc.2007.0062 |
|
Gene signatures and breast cancer network biology: Ready to the clinic? |
|
|
|
39 - 40 |
10.2122/gbc.2007.0063 |
|
Outcomes of breast cancer patients with and without BRCA1/2 mutations |
|
|
|
41 - 43 |
10.2122/gbc.2007.0064 |
|
Targeting Gastric Cancer: Inhibiting signal transduction pathways |
|
|
|
44 - 55 |
10.2122/gbc.2007.0065 |
|
Current Treatment of Gastric Cancer: More Complicated than Ever
|
|
|
|
56 - 59 |
10.2122/gbc.2006.0066 |
|
Asssessment of Laparoscopic Approach in Gastric Cancer
|
|
|
|
59 - 61 |
10.2122/gbc.2006.0067 |
|
Advances in Laparoscopic Gastrectomy |
|
|
|
62 - 65 |
10.2122/gbc.2007.0068 |
|
Laparoscopic Gastrectomy: Advances Enable Wide Clinical Application |
|
|
|
66 - 69 |
10.2122/gbc.2007.0069 |
|
Prognosis of BRCA and non BRCA mutation carriers |
|
|
|
70 - 72 |
10.2122/gbc.2007.0070 |
|
Choosing Preventive Intervention in BRCA mutation Carriers |
|
|
|
73 - 75 |
10.2122/gbc.2007.0071 |
|
A Study of Tissue Bcl-2 Expression and Its Serum Levels in Breast Cancer Patients |
|
|
|
76 - 83 |
10.2122/gbc.2007.0072 |
|
BREAKTHROUGH
HUMAN GENOME GENETIC VARIATION AND CLINIC |
|
|
|
1 - 8 |
|
|
Incorporating Genetic Testing for Guided Prevention of Contralateral Breast Cancer
|
|
|
|
9 - 12 |
|
|
Minimal residual disease in breast cancer: Can it be used as prognostic marker? |
|
|
|
13 - 15 |
|
|
Preventing Contralateral Breast Cancer |
|
|
|
16 - 18 |
|
|
Cancer origin and Metastasis - Does Local Control Affect Overall Survival for Solid Cancer? |
|
|
|
19 - 21 |
|
|
Endoscopic Mucosal Resection - Is safe and Effective for Early Diffuse-type Gastric Cancer? |
|
|
|
22 - 24 |
|
|
Benefits and harms in avoiding Axilla Lymphadenectomy in Breast Cancer |
|
|
|
25 - 27 |
|
|
Targeting HER2 Breast Cancer With Trastuzumab, Lapatinib and Other Novel Agents: Clinical Success and Resistance |
|
|
|
28 - 31 |
10.2122/gbc.2008.0080 |
|
Treatment of Localized Gastric Adenocarcinoma |
|
|
|
74 - 79 |
|
|
Prognostic Value of Epidermal Growth Factor Receptor in Breast Cancer: An Indian Experience |
|
|
|
56 - 64 |
10.2122/gbc.2008.0082 |
|
Tailoring surgery for breast cancer – Genetic Testing-based current practice and promises with Genomewide Association studies |
|
|
|
45 - 52 |
10.2122/gbc.2008.0083 |
|
Bevacizumab for metastatic breast cancer – Promise and Concerns |
|
|
|
53 - 55 |
10.2122/gbc.2008.0084 |
|
Structural genomic variation: Human Copy Number Variation Promise Towards Personalized Medicine |
|
|
|
65 - 68 |
10.2122/gbc.2008.0085 |
|
Da Vinci System for Robotic Rectal Cancer Surgery |
|
|
|
69 - 70 |
10.2122/gbc.2008.0086 |
|
VEGF and EGFR Antagonists for Gastric Cancer |
|
|
|
71 - 73 |
10.2122/gbc.2008.0087 |
|
Personal genomics and practical personalized medicine – Overcoming challenges? |
|
|
|
80 - 82 |
10.2122/gbc.2008.0088 |
|
Genetics and personal genome towards personalized breast cancer local control. |
|
|
|
83 - 85 |
10.2122/gbc.2008.0089 |
|
High-volume surgeons improve esophagus cancer oncological outcomes. |
|
|
|
86 - 88 |
10.2122/gbc.2008.0090 |
|
Genetic variation –SNPs/CNVs- and potential anticancer applications. |
|
|
|
89 - 91 |
10.2122/gbc.2008.0091 |
|
Laparoscopic colectomy for cancer. |
|
|
|
92 - 95 |
10.2122/gbc.2008.0092 |
|
Treatment of Localized Gastric Adenocarcinoma |
|
|
|
96 - 109 |
10.2122/gbc.2008.0093 |
|
Epidermal Growth Factor Receptor perspectives for Breast Cancer.
|
|
|
|
110 - 112 |
10.2122/gbc.2008.0094 |
|
D2 vs. D4 lymphadenectomy for gastric cancer. |
|
|
|
113 - 117 |
10.2122/gbc.2008.0095 |
|
DNA variation-based research including GWA studies may yield in understanding “genotype-phenotype mapping” through innovative causative network brilliant models |
|
|
|
1 - 2 |
|
|
H. pylori-diet and genetic factors interactions: Quantitative genetics gastric cancer targeted screening and prevention |
|
|
|
6 - 12 |
|
|
Targeted Agents and Biomarkers Promises and Pitfalls: Personal Genomics, Bioinformatics and Systems Biology Drive Novel Drugs Discovery and Markers for Personalized Cancer Biomedicine.
|
|
|
|
|
|
|
Personal Genetics and impact on breast surgeon |
|
|
|
29 - 31 |
|
|
Robotic Surgery: New Era in the Treatment of Solid Cancer. |
|
|
|
13 - 18 |
|
|
Solid cancer is a highly complex-heterogeneous disease. |
|
|
|
3 - 5 |
|
|
KRAS AND SIGNALING NETWORK: NEW THINK NEW DRUGS ERA |
|
|
|
19 - 24 |
|
|
Laparoscopic Gastrectomy: Evidence for improved QOL |
|
|
|
32 - 34 |
|
|
Laparoscopic Gastrectomy: HIGH-VOLUME SURGEONS |
|
|
|
25 - 28 |
|
|
Bevacizumab: Limitations for Breast Cancer Treatment |
|
|
|
29 - 30 |
|
|
New era in cancer surgical treatment |
|
|
|
31 - 35 |
|
|
Impact of genetics and genomics in breast cancer surgery |
|
|
|
36 - 38 |
|
|
Personalized Molecular cancer-targeted therapy |
|
|
|
39 - 46 |
|
|
Rectal cancer resection |
|
|
|
47 - 49 |
|
|
Laparoscopic Colectomy for Colon Cancer |
|
|
|
50 - 52 |
|
|
Personal genomics for early Breast cancer
How targeted therapy, genetics and personal genomics may prevent local failures and improve Local outcomes. |
|
|
|
53 - 69 |
|
|
Systems medicine for a next-generation of biomarkers and drugs: Changing poor cancer outcomes. |
|
|
|
1 - 23 |
|
|
Open or laparoscopic colorectal cancer resection: standardization and lymph nodes retried |
|
|
|
34 - 35 |
|
|
Low anterior rectal resection for rectal cancer: Why laparoscopic or robotic surgery may improve outcomes? |
|
|
|
29 - 30 |
|
|
Laparoscopic D2 gastrectomy: A new horizon even in the West |
|
|
|
31 - 33 |
|
|
Very early (T1a,bN0) breast cancer: HER2 and algorithmic approach to predict and treat patients at high recurrence risk |
|
|
|
36 - 44 |
|
|
Nipple-Sparing Mastectomy |
|
|
|
27 - 28 |
|
|
Why Gastric and Breast Cancer Journal ? CDH1 and HER2 |
|
|
|
24 - 26 |
|
| |
The new era of systems medicine and cancer networks |
|
|
|
45 - 50 |
|
| |
Breast cancer: Trastuzumab for HER2-positive patients and molecular systems approach |
|
|
|
51 - 54 |
|
| |
Challenges for personalized medicine: A 2020 vision |
|
|
|
55 - 59 |
|
| |
Advances in laparoscopic gastrectomy for early and advanced resectable gastric cancer |
|
|
|
60 - 64 |
|
| |
Endoscopic submucosal dissection for gastric tube cancer after esophagectomy |
|
|
|
65 - 67 |
|
| |
Challenges and expectations for novel biologics discovery in HER2-negative breast cancer |
|
|
|
68 - 69 |
|
|
Genetic geographical ancestry and breast cancer: Exploring potential phenotypic clinical differences in patients from Africa and Europe |
|
|
|
70 - 72 |
10.2122/gbc.2010.0125 |
| |
Decision-making treatment for early breast cancer and future perspectives |
|
|
|
73 - 82 |
|
|
Reversing Cancer and Ageing: Multiple Personal Genomes, Life Complexity and Myriad Clinical Challenges |
|
|
|
83 - 87 |
10.2122/gbc.2010.0127 |
|
Selection and identification of DNA aptamers to gastric cancer cell SGC-7901
|
|
|
|
119-126 |
10.2122/gbc.2010.0128 |
|
Cetuximab, panitumumab and bevacizumab resistance in colorectal cancer: Are molecular networks the solution? |
|
|
|
88 - 94 |
10.2122/gbc.2010.0129 |
|
Comparative-effectiveness research and personalized medicine: Trends and debate |
|
|
|
95 - 101 |
10.2122/gbc.2010.0130 |
|
Evidence-based laparoscopic surgery for low rectal cancer |
|
|
|
102-105 |
10.2122/gbc.2010.0131 |
|
Trastuzumab for small HER2-positive breast cancer? Uncertainty and new research directions |
|
|
|
106-109 |
10.2122/gbc.2010.0132 |
|
Intellectual innovation and new technology in surgical oncology |
|
|
|
110-112 |
10.2122/gbc.2010.0133 |
|
Western challenges with esophagectomy and follow-up |
|
|
|
113-115 |
10.2122/gbc.2010.0134 |
|
Standardizing colorectal cancer treatment
|
|
|
|
116-118 |
10.2122/gbc.2010.0135 |
|
Next-generation management of breast and gastric cancer |
|
|
|
127-143 |
10.2122/gbc.2010.0136 |
|
Sequencing Cancer Genome and investigating biomedical systems for improving surgical oncology |
|
|
|
144-149 |
10.2122/gbc.2010.0137 |
|
Whole-genome sequencing and epigenome analysis revolutionize biomedical sciences |
|
|
|
150-156 |
10.2122/gbc.2010.0138 |
|
Biomarkers for personalizing health: concerns, challenges and prospects |
|
|
|
157-162 |
10.2122/gbc.2010.0139 |
|
KRAS-targeting agents and beyond for colorectal cancer treatment |
|
|
|
163-169 |
10.2122/gbc.2010.0140 |
|
PLX4032: A novel effective anti-melanoma drug and new ways to overcome resistance |
|
|
|
170-174 |
10.2122/gbc.2010.0141 |
|
Colorectal cancer targeted treatment: advances and resistance |
|
|
|
186-192 |
10.2122/gbc.2010.0142 |
|
Trastuzumab: Isolated success in the adjuvant setting and a paradigm for moving toward network oncology |
|
|
|
193-198 |
10.2122/gbc.2010.0143 |
|
Personalized medicine: How and when, if ever, huge challenges could be overcome? |
|
|
|
175-185 |
10.2122/gbc.2010.0144 |
|
Totally robotic surgery for rectal cancer treatment: Advances and challenges |
|
|
|
199-201 |
10.2122/gbc.2010.0145 |
| |
Cetuximab: Explaining resistance and disappointing new results
|
|
|
|
25 - 29 |
|
|
Eribulin, epigenome and miRNAs cancer therapeutics targets - Beyond?
|
|
|
|
1 - 18 |
|
|
To test my genome? |
|
|
|
19 - 24 |
|
| |
Breast cancer: New key phase 3 trials data on sentinel node, recurrence biopsy and bevacizumab
|
|
|
|
43 - 46 |
|
|
Challenges in reaching true robust novel breast cancer markers |
|
|
|
36 - 42 |
|
|
Multimodal treatment including trastuzumab for gastroesophageal junction cancer: Controversy, and individualized decision.
|
|
|
|
30 - 35 |
|
|
MicroRNAs: A new class of therapeutic targets in cancer
|
|
|
|
53 - 58 |
|
| |
Family history and BRCA testing: Challenges in deciding between risk-reducing surgery and surveillance including MRI
|
|
|
|
47 - 52 |
|
|
From Genome Sequencing to Regulatory Circuits and from Traditional to Network Medicine. |
|
|
|
59-67 |
10.2122/gbc.2011.0154 |
|
Computational Biology, Quantitative Genetics and International Consortiums. |
|
|
|
68-72 |
10.2122/gbc.2011.0155 |
|
Cancer prevention and prophylactic surgery: Standards and GWAS-based perspectives. |
|
|
|
116-122 |
10.2122/gbc.2011.0156 |
|
Gastric cancer: Practice, Targeted Advances and novel genomics therapeutic approaches. |
|
|
|
73 -78 |
10.2122/gbc.2011.0157 |
|
Sequencing Cancer Genome shapes new ways in surgical oncology. |
|
|
|
109-115 |
10.2122/gbc.2011.0158 |
|
miRNAs gene expression regulation and their role in cancer prediction and therapy. |
|
|
|
79-84 |
10.2122/gbc.2011.0159 |
|
New GWAS new hope for disease-risk prediction, prevention, and therapy. |
|
|
|
85-90 |
10.2122/gbc.2011.0160 |
|
Aggressiveness and Complexity of Pancreatic Cancer: Research focused on tumorigenesis-based prevention or metastasis-based treatment? |
|
|
|
91-93 |
10.2122/gbc.2011.0161 |
|
Cetuximab limitations and renew interest in surgical resection and research advances for improving stage IV colorectal cancer outcome. |
|
|
|
94-96 |
10.2122/gbc.2011.0162 |
|
Family history and BRCA testing change surgery for breast cancer in the USA. |
|
|
|
97-99 |
10.2122/gbc.2011.0163 |
|
Standard and new treatment strategy to prevent melanoma recurrence. |
|
|
|
100-102 |
10.2122/gbc.2011.0164 |
|
Breast cancer biomarker: Advances, validation and novel discoveries. |
|
|
|
113-130 |
10.2122/gbc.2011.0165 |
|
Genotyping vs. exome sequencing for cancer. |
|
|
|
103-105 |
10.2122/gbc.2011.0166 |
|
Advances and challenges for laparoscopic rectal cancer surgery. |
|
|
|
106-108 |
10.2122/gbc.2011.0167 |
|
Selecting robotic and laparoscopic surgery in surgical oncology: fast progress but need for evidence. |
|
|
|
192-199 |
10.2122/gbc.2011.0168 |
|
Atlantis Mystery and Missing Heritability |
|
|
|
139-145 |
10.2122/gbc.2011.0169 |
|
Network Biology-Based Medicine |
|
|
|
131-138 |
10.2122/gbc.2011.0170 |
|
Avoiding axilla lymph node dissection for selected breast cancer: New sentinel lymph node dissection practice-changing trials. |
|
|
|
187-191 |
10.2122/gbc.2011.0171 |
|
Improving Pancreatic Cancer Treatment with Combinatorial Chemotherapy Regimen and Erlotinib. |
|
|
|
151-153 |
10.2122/gbc.2011.0172 |
|
Intracorporeal anastomosis after laparoscopic right colectomy for cancer |
|
|
|
154-156 |
10.2122/gbc.2011.0173 |
|
Surgical resection and research advances for improving stage IV colorectal cancer outcome |
|
|
|
157-158 |
10.2122/gbc.2011.0174 |
|
Melanoma and recurrence: Advances and challenges in the prevention and treatment strategies |
|
|
|
159-160 |
10.2122/gbc.2011.0175 |
|
Laparoscopic sphincter-saving surgery for rectal cancer |
|
|
|
161-164 |
10.2122/gbc.2011.0176 |
|
Single-port laparoscopic-assisted vaginal hysterectomy: Safe and effective advance |
|
|
|
165-166 |
10.2122/gbc.2011.0177 |
|
Inferior mesenteric artery and colorectal cancer: Ligation vs. preservation with laparoscopic node dissection |
|
|
|
167-169 |
10.2122/gbc.2011.0178 |
|
Breast Cancer: Radiotherapy at the South Egypt Cancer Institute |
|
|
|
180-186 |
10.2122/gbc.2011.0179 |
|
Laparoscopic transanal sphincter preservation-rectal cancer resection |
|
|
|
170-172 |
10.2122/gbc.2011.0180 |
|
Gastric cancer recurrence and laparoscopic gastrectomy |
|
|
|
173-175 |
10.2122/gbc.2011.0181 |
|
Heritability and Prophylactic Surgery |
|
|
|
176-177 |
10.2122/gbc.2011.0182 |
|
Laparoscopic Total Gastrectomy: Preventing Gastric Cancer in CDH1 Mutation Carriers |
|
|
|
178-179 |
10.2122/gbc.2011.0183 |
|
Standard and Research for Ovarian Cancer: Emphasis on interactome-based tests for screening or treatment including HIPEC? |
|
|
|
146-150 |
10.2122/gbc.2011.0184 |
|
Epigenomics-based novel anticancer therapies. |
|
|
|
200-206 |
10.2122/gbc.2011.0185 |
|
Asymmetric open field-in-field can replace wedged fields in tangential whole breast irradiation |
|
|
|
250-255 |
10.2122/gbc.2011.0186 |
|
Assessing resistance to neoadjuvant treatment for breast cancer |
|
|
|
226-228 |
10.2122/gbc.2011.0187 |
|
Cytoreductive Surgery for Ovarian Cancer: Is Splenectomy indicated? |
|
|
|
229-231 |
10.2122/gbc.2011.0188 |
|
KRAS mutation testing: Why is it now not recommended for colorectal cancer EGFR inhibitors treatment decision? |
|
|
|
220-222 |
10.2122/gbc.2011.0189 |
|
Functional Genomics and Chromatin: Why understanding gene expression regulation is essential to revolutionize cancer therapy? |
|
|
|
207-213 |
10.2122/gbc.2011.0190 |
|
Peritoneal recurrence: The challenge in gastric cancer treatment and efforts to prevent |
|
|
|
232-234 |
10.2122/gbc.2011.0191 |
|
Total gastrectomy: Preventing hereditary diffuse gastric cancer |
|
|
|
235-237 |
10.2122/gbc.2011.0192 |
|
Breast cancer risk-reducing surgery and BRCA testing |
|
|
|
238-240 |
10.2122/gbc.2011.0193 |
|
Sigmoid or rectal cancer: do patients benefit from high ligation of inferior mesenteric artery? |
|
|
|
241-243 |
10.2122/gbc.2011.0194 |
|
HER2 status-based selection of gastric cancer patients for trastuzumab treatment. |
|
|
|
244-246 |
10.2122/gbc.2011.0195 |
|
How to prevent or treat hereditary diffuse gastric cancer? |
|
|
|
247-249 |
10.2122/gbc.2011.0196 |
|
Translational advances and challenges for pharmacogenomics-based prescription of drugs |
|
|
|
256-261 |
10.2122/gbc.2011.0197 |
|
Field-in-Field Technique as a Treatment of Choice in Tangential Whole Breast Irradiation |
|
|
|
223-225 |
10.2122/gbc.2011.0198 |
|
Novel Techniques in Radiation Therapy |
|
|
|
214-216 |
10.2122/gbc.2011.0199 |
|
Minimally invasive total mesorectal excision for extraperitoneal rectal cancer: Why patients should seek specialized hospitals and surgeons? |
|
|
|
217-219 |
10.2122/gbc.2011.0200 |
|
Whole-genome sequence: from research to clinical practice? |
|
|
|
7-12 |
|
| |
Inhibiting mTOR and VEGF signaling in pancreatic neuroendocrine tumors. |
|
|
|
13-19 |
|
|
New standard targeted therapy for pancreatic neuroendocrine tumors |
|
|
|
44-49 |
|
| |
The up and down of KRAS testing for personalized colorectal cancer treatment |
|
|
|
29-31 |
|
|
From whole-genome sequencing to gene expression regulation: Perspectives for improving oncological outcomes. |
|
|
|
1-6 |
|
|
Gastric cancer recurrence: Is it influenced by laparoscopic gastrectomy? |
|
|
|
20-22 |
|
|
Monitoring EGFR plasma levels: Is it a biomarker for colorectal cancer? |
|
|
|
32-34 |
|
|
Pancreatic adenocarcinoma: a grand challenge |
|
|
|
35-37 |
|
|
Laparoscopic Sentinel Node Biopsy in Solid Cancer |
|
|
|
23-25 |
|
| |
From Asia to Europe: Laparoscopic and robotic gastrectomy for cancer |
|
|
|
26-28 |
|
|
Laparoscopic Right colectomy |
|
|
|
38-40 |
10.2122/gbc.2012.0211 |
|
Economic crisis and laparoscopic surgery |
|
|
|
41-43 |
|
|
Solid cancer: Evaluating potential efficacy of epigenetic drugs. |
|
|
|
102-107 |
10.2122/gbc.2012.0213 |
|
Progress in treating laparoscopically advanced gastric cancer |
|
|
|
79-81 |
10.2122/gbc.2012.0214 |
|
Precision medicine: Neoadjuvant treatment and laparoscopic rectal cancer resection |
|
|
|
82-84 |
10.2122/gbc.2012.0215 |
|
Management of advanced non-clear cell renal carcinoma. |
|
|
|
94-101 |
10.2122/gbc.2012.0216 |
|
Laparoscopic gastrectomy: Challenges and perspectives in predicting morbidity and relapse risk in gastric cancer.
|
|
|
|
85-87 |
10.2122/gbc.2012.0217 |
|
Safety and quality of life improvement expand laparoscopic resection for gastric cancer |
|
|
|
88-90 |
10.2122/gbc.2012.0218 |
|
Pre-treatment diagnostics of esophageal cancer and the role of EUS |
|
|
|
91-93 |
10.2122/gbc.2012.0219 |
|
Science and technology: revealing genome networks for improving health |
|
|
|
58-64 |
10.2122/gbc.2012.0220 |
|
Tumor heterogeneity-based personalized oncology
|
|
|
|
72-78 |
10.2122/gbc.2012.0221 |
|
Genome-based diagnostics and therapeutics in personalized cancer therapy: Can the challenges be overcome? |
|
|
|
53-57 |
10.2122/gbc.2012.0222 |
|
Transcriptome mapping: ER-binding sites dynamics reveal new strategy for breast cancer biomarkers |
|
|
|
50-52 |
10.2122/gbc.2012.0223 |
|
‘Sequence everything' strategy in the clinical cancer genome era |
|
|
|
65-71 |
10.2122/gbc.2012.0224 |
|
Predictive molecular tools to personalized gastric cancer targeted therapy. |
|
|
|
166-179 |
10.2122/gbc.2012.0225 |
|
Robots and surgeons: Do patients benefit?
|
|
|
|
140-142 |
10.2122/gbc.2012.0226 |
|
The emerging role of miRNAs in translational cancer medicine. |
|
|
|
180-195 |
10.2122/gbc.2012.0227 |
|
Cancer single pathways inhibitors: More resistance than durable success in the clinic |
|
|
|
111-117 |
10.2122/gbc.2012.0228 |
|
Tumor diversity: Implementing NGS into clinic |
|
|
|
121-126 |
10.2122/gbc.2012.0229 |
|
Neoadjuvant treatment and laparoscopic rectal cancer: Precision genomic medicine essential for improving patient's outcomes. |
|
|
|
143-145 |
10.2122/gbc.2012.0230 |
|
Gastric cancer perspectives: Laparoscopic surgery and systems approach polypharmacology. |
|
|
|
146-148 |
10.2122/gbc.2012.0231 |
|
Breast cancer advances in clinical cancer genome era: from conventional to integrative genome analysis. |
|
|
|
149-150 |
10.2122/gbc.2012.0232 |
|
100 breast cancer genome sequencing: Heterogeneity-based diagnostic and therapeutic perspectives. |
|
|
|
127-130 |
10.2122/gbc.2012.0233 |
|
Overcoming resistance to cetuximab or panitumumab in KRAS wild-type colorectal cancer. |
|
|
|
131-134 |
10.2122/gbc.2012.0234 |
|
Resistance to everolimus treatment of renal cancer, intratumor heterogeneity and new therapeutic approaches. |
|
|
|
118-120 |
10.2122/gbc.2012.0235 |
|
Novel breast cancer subtypes with integrative genomic and transcriptome analysis. |
|
|
|
108-110 |
10.2122/gbc.2012.0236 |
|
Vemurafenib plus cetuximab or gefitinib for BRAF(V600E) mutant colorectal cancer. |
|
|
|
151-153 |
10.2122/gbc.2012.0237 |
|
Preoperative chemoradiotherapy for rectal cancer: Why revision and concerns are now shaped? |
|
|
|
154-156 |
10.2122/gbc.2012.0238 |
|
Total mesorectal excision for rectal cancer: Laparoscopic or robotic approach? |
|
|
|
157-159 |
10.2122/gbc.2012.0239 |
|
Dual inhibition of HER2 for a safe increase of efficacy in breast cancer. |
|
|
|
160-162 |
10.2122/gbc.2012.0240 |
|
Everolimus added to aromatase inhibitors for improving hormone-receptor-positive breast cancer outcomes. |
|
|
|
163-165 |
10.2122/gbc.2012.0241 |
|
Triple-negative breast cancer: From microarrays basal-like subtype to NGS molecular classification and new drugs development. |
|
|
|
135-139 |
10.2122/gbc.2012.0242 |
| |
Tyrosine kinase inhibitors expand indications for surgical resection of advanced GIST.
|
|
|
|
233-235 |
10.2122/gbc.2012.0243 |
| |
Healthy longevity: Approaching life mystery in genome science era. |
|
|
|
226-232 |
10.2122/gbc.2012.0244 |
| |
Cellular signaling networks exploration for clinical applications. |
|
|
|
221-225 |
10.2122/gbc.2012.0245 |
| |
Personalized medicine through genome science and network biology advances. |
|
|
|
216-220 |
10.2122/gbc.2012.0246 |
|
Adding Fulvestrant to Anastrozole prolongs survival in Breast Cancer. |
|
|
|
211-215 |
10.2122/gbc.2012.0247 |
| |
Innovative drug targets: Cooperative DNA, RNA and proteins networks. |
|
|
|
196-202 |
10.2122/gbc.2012.0248 |
|
Improving survival with trastuzumab emtansine for HER2-positive breast cancer. |
|
|
|
203-207 |
10.2122/gbc.2012.0249 |
| |
Cancer Biomarkers: Pitfalls with traditional research and novel integrated genome analysis opportunities. |
|
|
|
236-238 |
10.2122/gbc.2012.0250 |
| |
Trametinib plus dabrafenib : Targeting RAS-MAPK pathway for BRAF V600-mutant melanoma. |
|
|
|
208-210 |
10.2122/gbc.2012.0251 |
| |
Advances and limitations with multimodal treatment of Colorectal cancer liver metastases. |
|
|
|
239-241 |
10.2122/gbc.2012.0252 |
